Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study
Glioblastoma (GBM) is the most common and aggressive type of tumour arising from the central nervous system. GBM remains an incurable disease despite advancement in therapies, with overall survival of approximately 15 months. Recent literature has highlighted that GBM releases tumoural content which...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.681130/full |
id |
doaj-be369566ee874d27a0bf30ab00df39cd |
---|---|
record_format |
Article |
spelling |
doaj-be369566ee874d27a0bf30ab00df39cd2021-06-03T14:18:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-06-011110.3389/fonc.2021.681130681130Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot StudyJuliana Müller Bark0Juliana Müller Bark1Arutha Kulasinghe2Arutha Kulasinghe3Gunter Hartel4Paul Leo5Paul Leo6Majid Ebrahimi Warkiani7Rosalind L. Jeffree8Rosalind L. Jeffree9Rosalind L. Jeffree10Rosalind L. Jeffree11Benjamin Chua12Benjamin Chua13Bryan W. Day14Bryan W. Day15Bryan W. Day16Chamindie Punyadeera17Chamindie Punyadeera18Saliva and Liquid Biopsy Translational Laboratory, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaSaliva and Liquid Biopsy Translational Laboratory, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaDepartment of Statistics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaTranslational Genomics Group, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaThe School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, AustraliaDepartment of Statistics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AustraliaFaculty of Medicine, University of Queensland, Brisbane, QLD, AustraliaKenneth G. Jamieson Department of Neurosurgery, Royal Brisbane and Women’s Hospital, Brisbane, QLD, AustraliaCell and Molecular Biology Department, Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer MRI, Brisbane, QLD, AustraliaFaculty of Medicine, University of Queensland, Brisbane, QLD, AustraliaCancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane, QLD, AustraliaFaculty of Medicine, University of Queensland, Brisbane, QLD, AustraliaCell and Molecular Biology Department, Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer MRI, Brisbane, QLD, Australia0School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaSaliva and Liquid Biopsy Translational Laboratory, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaGlioblastoma (GBM) is the most common and aggressive type of tumour arising from the central nervous system. GBM remains an incurable disease despite advancement in therapies, with overall survival of approximately 15 months. Recent literature has highlighted that GBM releases tumoural content which crosses the blood-brain barrier (BBB) and is detected in patients’ blood, such as circulating tumour cells (CTCs). CTCs carry tumour information and have shown promise as prognostic and predictive biomarkers in different cancer types. Currently, there is limited data for the clinical utility of CTCs in GBM. Here, we report the use of spiral microfluidic technology to isolate CTCs from whole blood of newly diagnosed GBM patients before and after surgery, followed by characterization for GFAP, cell-surface vimentin protein expression and EGFR amplification. CTCs were found in 13 out of 20 patients (9/20 before surgery and 11/19 after surgery). Patients with CTC counts equal to 0 after surgery had a significantly longer recurrence-free survival (p=0.0370). This is the first investigation using the spiral microfluidics technology for the enrichment of CTCs from GBM patients and these results support the use of this technology to better understand the clinical value of CTCs in the management of GBM in future studies.https://www.frontiersin.org/articles/10.3389/fonc.2021.681130/fullglioblastomaliquid biopsycirculating tumour cellsgliomaspiral microfluidic technology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juliana Müller Bark Juliana Müller Bark Arutha Kulasinghe Arutha Kulasinghe Gunter Hartel Paul Leo Paul Leo Majid Ebrahimi Warkiani Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Benjamin Chua Benjamin Chua Bryan W. Day Bryan W. Day Bryan W. Day Chamindie Punyadeera Chamindie Punyadeera |
spellingShingle |
Juliana Müller Bark Juliana Müller Bark Arutha Kulasinghe Arutha Kulasinghe Gunter Hartel Paul Leo Paul Leo Majid Ebrahimi Warkiani Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Benjamin Chua Benjamin Chua Bryan W. Day Bryan W. Day Bryan W. Day Chamindie Punyadeera Chamindie Punyadeera Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study Frontiers in Oncology glioblastoma liquid biopsy circulating tumour cells glioma spiral microfluidic technology |
author_facet |
Juliana Müller Bark Juliana Müller Bark Arutha Kulasinghe Arutha Kulasinghe Gunter Hartel Paul Leo Paul Leo Majid Ebrahimi Warkiani Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Rosalind L. Jeffree Benjamin Chua Benjamin Chua Bryan W. Day Bryan W. Day Bryan W. Day Chamindie Punyadeera Chamindie Punyadeera |
author_sort |
Juliana Müller Bark |
title |
Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study |
title_short |
Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study |
title_full |
Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study |
title_fullStr |
Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study |
title_full_unstemmed |
Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study |
title_sort |
isolation of circulating tumour cells in patients with glioblastoma using spiral microfluidic technology – a pilot study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-06-01 |
description |
Glioblastoma (GBM) is the most common and aggressive type of tumour arising from the central nervous system. GBM remains an incurable disease despite advancement in therapies, with overall survival of approximately 15 months. Recent literature has highlighted that GBM releases tumoural content which crosses the blood-brain barrier (BBB) and is detected in patients’ blood, such as circulating tumour cells (CTCs). CTCs carry tumour information and have shown promise as prognostic and predictive biomarkers in different cancer types. Currently, there is limited data for the clinical utility of CTCs in GBM. Here, we report the use of spiral microfluidic technology to isolate CTCs from whole blood of newly diagnosed GBM patients before and after surgery, followed by characterization for GFAP, cell-surface vimentin protein expression and EGFR amplification. CTCs were found in 13 out of 20 patients (9/20 before surgery and 11/19 after surgery). Patients with CTC counts equal to 0 after surgery had a significantly longer recurrence-free survival (p=0.0370). This is the first investigation using the spiral microfluidics technology for the enrichment of CTCs from GBM patients and these results support the use of this technology to better understand the clinical value of CTCs in the management of GBM in future studies. |
topic |
glioblastoma liquid biopsy circulating tumour cells glioma spiral microfluidic technology |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.681130/full |
work_keys_str_mv |
AT julianamullerbark isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT julianamullerbark isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT aruthakulasinghe isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT aruthakulasinghe isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT gunterhartel isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT paulleo isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT paulleo isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT majidebrahimiwarkiani isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT rosalindljeffree isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT rosalindljeffree isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT rosalindljeffree isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT rosalindljeffree isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT benjaminchua isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT benjaminchua isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT bryanwday isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT bryanwday isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT bryanwday isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT chamindiepunyadeera isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy AT chamindiepunyadeera isolationofcirculatingtumourcellsinpatientswithglioblastomausingspiralmicrofluidictechnologyapilotstudy |
_version_ |
1721399278712127488 |